引用次数
引用: 6,025
H-指数: 34
I10-指数 : 72
出版物: 261
Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status
Ryan D. Cassaday , Karen Schiavo , Leona Holmberg , Ajay K. Gopal
Blood 122 ( 21) 2106 -2106
3
2013
A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy.
Chand Khanna , Seuli M. Bose , Jennifer Prehn , David Hayden
Clinical Cancer Research 8 ( 7) 2406 -2412
53
2002
Clinical and Molecular Characteristics of Therapy-Related Acute Lymphoblastic Leukemia
Matt Kalaycio , Donna M. Abounader , Ronald Sobecks , Bartlomiej Przychodzen
Blood 130 3993 -3993
2017
Clinical Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients with Richter's Transformation (RT) to Aggressive Non-Hodgkin Lymphoma (aNHL): a Single-Institution Experience
Mohamed L Sorror , Ryan D. Cassaday , Mazyar Shadman , Leona Holmberg
Blood 130 4308 -4308
2017
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Global Phase 3 INO-VATE Trial: Efficacy and Safety By Baseline CD22 Expression Level
Daniel J. DeAngelo , Ryan D. Cassaday , Hagop M. Kantarjian , Erik Vandendries
Blood 130 1272 -1272
4
2017
Barriers to Successful Implementation of Precision Medicine to the Treatment of Refractory AML: Lessons Learned
Evandro D Bezerra , Sylvia Chien , Timothy Martins , Cody Hammer
Blood 130 4622 -4622
2017
Anti-CD45 Radioimmunotherapy Followed By Haploidentical Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Leukemia or High-Risk MDS
Frederick R. Appelbaum , Brenda M. Sandmaier , Ted Gooley , Joseph G. Rajendran
Blood 130 2048 -2048
1
2017
Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis
Vivian G. Oehler , Vivian G. Oehler , Vivian G. Oehler , Ryan D. Cassaday
Blood 136 28 -30
2020
Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma
Ryan D. Cassaday , Ryan D. Cassaday , Ryan D. Cassaday , Mazyar Shadman
Blood 136 1 -2
2020
Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study
Ryan D. Cassaday , Jonathan R. Fromm , Mazyar Shadman , Edus H. Warren
Blood 136 16 -18
2020
A Phase II Trial Evaluating the Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed By Autologous Transplantation, for High-Risk Relapsed or Refractory Non-Hodgkin's Lymphoma
Frederick R. Appelbaum , Frederick R. Appelbaum , Ted Gooley , Ryan D. Cassaday
Blood 130 2018 -2018
1
2017
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
Ryan D. Cassaday , Khaled Ramadan , Chantal Léger , Heather Leitch
Current Oncology 28 ( 1) 252 -259
2020
Phase II Study of Mega-Dose 90Y-Ibritumomab Tiuxetan, Fludarabine and Low-Dose TBI Followed By Allogeneic Hematopoietic Transplantation for Relapsed or Refractory Aggressive Large B-Cell Lymphoma: Long-Term Outcomes
Ryan D. Cassaday , Manuela C. Matesan , Sherilyn A. Tuazon , Johnnie J. Orozco
Transplantation and Cellular Therapy 27 ( 3)
2021
Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial
Ryan D. Cassaday , Ryan D. Cassaday , Jonathan R. Fromm , Jonathan R. Fromm
Blood 130 2806 -2806
6
2017
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Daniel J. DeAngelo , Ryan D. Cassaday , Hagop M. Kantarjian , Erik Vandendries
Clinical Cancer Research 27 ( 10) 2742 -2754
1
2021
Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission
Daniel J. Landsburg , Marissa K. Falkiewicz , Joseph Maly , Kristie A. Blum
Journal of Clinical Oncology 35 ( 20) 2260 -2267
137
2017
Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
Hagop M. Kantarjian , Wendy Stock , Ryan D. Cassaday , Daniel J. DeAngelo
Blood 134 1344 -1344
2
2019
Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Alexandre V. Hirayama , Jordan Gauthier , Kevin A. Hay , Alyssa Sheih
Blood 132 1680 -1680
11
2018
Use of Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL) in an Expanded Access Setting at Our Cancer Consortium
Kelda M Gardner , Kathleen Shannon Dorcy , Rachele O'Leary , Donelle Rizzuto
Blood 132 2710 -2710
2018